Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Unknown

Mouse and cell culture studies suggest a derivative of griseofulvin that inhibits centrosomal clustering could help treat cancer. In a panel of cancer cell lines, the derivative inhibited proliferation with IC50 values of 1-2.5 mM. In mouse xenograft models of multiple myeloma and colon cancer, intraperitoneal injection of the griseofulvin derivative decreased tumor growth and increased survival compared with vehicle injection. Next steps include optimizing the compound and evaluating toxicity.

SciBX 5(39); doi:10.1038/scibx.2012.1027
Published online Oct. 4, 2012

Patented for use in treating malignant conditions; available for licensing

Raab, M.S. et al. Cancer Res.; published online Aug. 31, 2012;
doi:10.1158/0008-5472.CAN-12-2026
Contact: Marc S. Raab, German Cancer Research Center, Heidelberg, Germany
e-mail:

m.raab@dkfz.de